Fundraising FoxRA Capital — 2016 Investments
5 investments dated 2016 · listed companies and verified rows first · show all
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Jay Strum(Executive Officer)Norman Sharpless(Director)Mark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)
Board seatPeter Kolchinsky· per SEC Form D
Co-investorsLumira VenturesMountain Group CapitalSolasta VenturesHatteras Venture Partners
LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Gregory L. Verdine(Executive Officer, Director)Gregory Verdine, Ph.D.
BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)
Co-investorsARCH Venture PartnersGV (Google Ventures)Aisling CapitalAlexandriaBezos ExpeditionsBlue Pool Capital+7 more
Moderna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.
BiotechDeep TechMedical DevicesCambridge, US
Robert Langer(Founder)Noubar Afeyan, Ph.D.(Co-founder and Chairman, Moderna; CEO, Flagship Pioneering)Lorence Kim(Executive Officer)inJames R. Kasinger(Executive Officer)inStephen Hoge(Executive Officer)inDerrick Rossi(Founder)
Co-investorsAglae VenturesBlackstone Life SciencesFlagship PioneeringFPVKhosla VenturesLingotto+5 more
HealthtechLexington, US
Michael Cima, Ph.D.(Director)Rahul Dhanda(Senior Vice President, Corporate Development)inJohn McDonough(Chief Executive Officer)inTom Lowery, Ph.D.(Chief Scientific Officer)Michael Gibbs, Esq.(Vice President and General Counsel)Joanne Spadoro, Ph.D.(Chief Operating Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersIn-Q-TelArcus VenturesFlagship VenturesFlybridge Capital Partners+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.